13 results about "Skin atrophy" patented technology

The invention discloses a phlebitis treatment gel containing a coptis chinensis-wine-treated rhubarb compound component and a preparation method of the phlebitis treatment gel. The active ingredients of the gel are coptis chinensis, rheum officinale and wine-treated rheum officinale in a mass ratio of (1.5-2.5): (1.5-2.5): 1, preferably 2: 2: 1. Lavender essential oil, tea tree essential oil, folium eucalypti essential oil and vinegar frankincense, radix trichosanthis and other traditional Chinese medicine auxiliary materials are used as auxiliary materials. The preparation method comprises the following steps: extracting twice with ethanol, mixing extracting solutions, adding borneol, menthol and essential oil, and finally gelling with carbomer. The phlebitis gel can be independently used or combined with indometacin to form dual-channel anti-inflammation, and the defects of skin atrophy, toxicity accumulation and the like of traditional phlebitis gel are overcome. The traditional Chinese medicine composition is clinically expanded and applied to first-stage pressure sores (without skin damage), acnes and mosquito bites, red and swollen of the first-stage pressure sores fade away within 3-5 days, red and swollen of the acnes are relieved by more than or equal to 60% when the traditional Chinese medicine composition is combined with oral medicine for 48 hours, the itching relieving effect on the mosquito bites is less than or equal to 30 minutes, and the curative effect on phlebitis is remarkably superior to that of 50% magnesium sulfate (Plt;

The present application belongs to the technical field of dermatosis treatment products, and particularly relates to a soft pelleted medicine and a preparation method thereof. The soft pelleted medicine is prepared from the following raw materials in parts by weight: 20-40 parts of Ramulus cinnamomi, 25-35 parts of Radix astragali, 5-15 parts of Semen persicae, 5-15 parts of Ophiopogon, 5-15 parts of Carthamus tinctorius, 15-30 parts of calcined Radix paeoniae alba, 10-20 parts of Radix angelicae sinensis, 15-30 parts of Radix rehmanniae preparata, 20-40 parts of Radix codonopsis, 5-15 parts of Radix paeoniae alba, 5-10 parts of Ephedra, 5-10 parts of Radix rubiae, 5-15 parts of Centella asiatica, 2-5 parts of Radix et Rhizoma aconiti, 5-10 parts of Salvinia natans, and 5-10 parts of Rhizoma zingiberis. The soft pelleted medicine provided by the present application has the main effects of warming yang and benefiting qi, promoting blood circulation to remove meridian obstruction, dispelling cold and dampness, removing blood stasis and promoting tissue regeneration, and is used for treating dermatosis such as scleroderma, frostbite, Raynaud's disease, skin atrophy, and the like, and particularly has remarkable effects on scleroderma, frostbite, Raynaud's disease, and skin atrophy.

The invention provides a traditional Chinese medicine composition for treating alopecia areata and a preparation method and application thereof, and belongs to the technical field of traditional Chinese medicine preparations. The traditional Chinese medicine composition is prepared from the following components in parts by mass: 10 to 30 parts of radix rehmanniae recen, 10 to 30 parts of radix rehmanniae preparata, 10 to 30 parts of caulis spatholobi, 10 to 30 parts of caulis polygoni multiflori, 30 to 50 parts of radix astragali, 10 to 20 parts of rhizoma chuanxiong, 10 to 30 parts of radix paeoniae alba, 5 to 20 parts of rhizoma gastrodiae, 5 to 20 parts of cordyceps sinensis, 10 to 30 parts of herba ecliptae, 10 to 30 parts of mulberry and 5 to 20 parts of fructus chaenomelis. The effect is stronger, and no side effect exists. The tincture prepared by the invention is a pure external preparation without systemic toxicity, has no side effects such as hirsutism and skin atrophy after long-term use, and is especially suitable for sensitive scalp patients.

The invention discloses a stem cell exosome composition as well as a preparation method and application thereof. The stem cell exosome composition is prepared from the following raw materials in parts by weight: 0.0000168 to 0.00004 part of umbilical cord mesenchymal stem cell exosome, 0.8 to 1.2 parts of polydeoxyribonucleotide, 1.44 to 2.16 parts of III type collagen, 0.31 to 0.48 part of sodium hyaluronate and 50 to 150 parts of normal saline. According to the application, the bioavailability and repairing efficiency of active ingredients in a corium layer can be remarkably improved, and the application has the advantage of remarkable effect on repairing intractable skin barrier damage, refractory sensitive skin and severe skin atrophy and elasticity loss caused by aging.

This invention relates to the field of natural product pharmaceuticals, and more particularly to a spirobroussonin compound, its preparation method, and its application. The spirobroussonin C provided by this invention is isolated from the paper mulberry tree. This compound can inhibit the release of the inflammatory factor IL-13 from human keratinocytes induced by IL-4 / TNF-α, exhibiting activity superior to the clinical drug dexamethasone and without cytotoxicity. It can significantly alleviate ear dryness and excessive angiogenesis in MC903-induced atopic dermatitis mice, reduce ear swelling, epidermal thickening, and transepidermal water loss, alleviate the trend of weight loss, reduce mast cell infiltration, and inhibit the expression of serum IgE and Th2-type cytokines such as IL-13, IL-4, and TSLP in ear tissue. No glucocorticoid-like side effects such as skin atrophy or metabolic disorders were observed with Spirobroussonin C within the experimental dose range.

The present invention includes compositions and methods for treating or preventing certain dermal disorders including dermal atrophy, pseudoscars, actinic keratosis, seborrheic or actinic keratoses, lentigines, focal areas of dermal thickening, and coarse wrinkles. In certain embodiments, the compositions useful within the invention comprise a therapeutically effective amount of a mTORC1 inhibitor and a dermatologically acceptable carrier.

This invention relates to the field of biomedical technology, and more particularly to the application of XPO1 inhibitors in the preparation of drugs for the topical treatment of pruritus. Experimental studies have shown that XPO1 inhibitors have significant therapeutic effects on chronic and complex pruritus models, and may be applicable to pruritus caused by various etiologies, possessing broad-spectrum therapeutic potential. By administering the drug topically, it primarily acts on the local skin, greatly avoiding the serious systemic side effects (such as hematological toxicity and gastrointestinal reactions) associated with oral XPO1 inhibitors. Simultaneously, it also avoids the local side effects such as skin atrophy caused by long-term use of potent hormones. This invention provides a novel drug option for the treatment of intractable pruritus and related inflammatory skin diseases.

The invention belongs to the technical field of traditional Chinese medicines, and discloses an application of coptis chinensis paste in preparation of a medicine for treating or preventing atopic dermatitis, and the coptis chinensis paste is used for treating the atopic dermatitis by repairing a skin barrier and regulating immune response. Pharmacodynamic verification proves that the rhizoma coptidis paste shows a good curative effect in the aspect of improving AD-like dermatitis symptoms, skin atrophy side effects similar to dexamethasone are not observed at a high dosage, and the rhizoma coptidis paste shows better treatment safety characteristics. According to the application disclosed by the invention, the action mechanism of the coptis chinensis cream for treating atopic dermatitis is defined, the coptis chinensis cream promotes synthesis of skin barrier structural protein to consolidate defense and effectively inhibits release of alarm elements such as TSLP / IL-33 to block inflammation initiation, finally, effector factors such as IL-4 / IL-13 and the like and IgE are reduced, inflammatory cell reactions such as mastocyte infiltration are relieved, and the curative effect of the coptis chinensis cream on atopic dermatitis is improved. Therefore, clinical symptoms and pathological changes of AD are improved.

The invention belongs to the technical field of medicines, and discloses a selenium-enriched brassica campestris extract and application thereof in preparation of a medicine for relieving psoriasis symptoms. Effective substances of the selenium-rich brassica campestris are extracted by using a specific extraction mode, the extract is further found to be capable of effectively relieving psoriasis symptoms, and when the effective selenium content in the extract is far lower than that of MSC, the extract still has a good curative effect and is safe and reliable. Other substances in the extract can be combined with the selenium element to achieve a synergistic treatment effect. The selenium-enriched brassica campestris is used as the unique raw material, so that the skin atrophy caused by hormone treatment and the infection risk caused by monoclonal antibody drugs in the traditional psoriasis therapy are thoroughly avoided.

The invention relates to a triamcinolone acetonide and econazole cream for promoting barrier repair and a preparation method of the triamcinolone acetonide and econazole cream. According to the triamcinolone acetonide and econazole cream, the brown algae extract rich in fucosan is creatively introduced, so that the triamcinolone acetonide and econazole cream keeps the original anti-inflammatory and anti-fungal curative effects, meanwhile, the risks of local adverse reactions such as skin atrophy and angiotelectasis caused by triamcinolone acetonide are effectively relieved, generation of fungal drug resistance is inhibited, and the triamcinolone acetonide and econazole cream has a good application prospect. The barrier repairing and moisturizing capabilities of the skin are obviously enhanced. Besides, the red algae extract is introduced into the cream formula, and the red algae extract and the brown algae extract play a synergistic effect, so that local adverse reactions are further relieved, fungal drug resistance is inhibited, and the barrier repairing and moisturizing capacity of the skin is enhanced.

The invention provides application of hydrolyzed hyaluronic acid or a salt thereof as an 11beta-HSD1 expression inhibitor. The application finds that hydrolyzed hyaluronic acid or a salt thereof can be used as a 11 [beta]-HSD1 expression inhibitor, and thus can be used for inhibiting excessive conversion of cortisol into cortisol, such as cortisol production. Further, the hydrolyzed hyaluronic acid or the salt thereof can prevent and / or alleviate skin problems caused by cortisol imbalance, such as skin aging such as reduced skin collagen and reduced skin microcosin, skin barrier injury, skin inflammation, slowed skin self-repairing speed, skin atrophy, and the like.

The invention relates to the field of natural product medicines, in particular to a spirocyclic broussoninine compound as well as a preparation method and application thereof. The spiroring broussonin compound spirobroussonin C provided by the invention is separated from the broussonetia papyrifera. The compound can inhibit IL-4 / TNF-alpha induced human keratinocyte from releasing an inflammatory factor IL-13, the activity of the compound is superior to that of a clinical drug dexamethasone, the compound is free of cytotoxicity, ear dryness and excessive angiogenesis of MC903 induced atopic dermatitis mice can be remarkably relieved, ear swelling, epidermis thickening and percutaneous moisture loss of the mice are reduced, and the compound has a good application prospect. The traditional Chinese medicine composition can be used for relieving the weight loss trend, relieving mast cell infiltration and inhibiting expression of Th2 type cytokines such as serum IgE and ear tissue IL-13, IL-4 and TSLP. In the experimental dosage range of Spirobroussonin C, side effects such as skin atrophy and metabolic disorder similar to glucocorticoid are not observed.

The present invention includes compositions and methods for treating or preventing certain dermal disorders including dermal atrophy, pseudoscars, actinic keratosis, seborrheic or actinic keratoses, lentigines, focal areas of dermal thickening, and coarse wrinkles. In certain embodiments, the compositions useful within the invention comprise a therapeutically effective amount of a mTORC1 inhibitor and a dermatologically acceptable carrier.